AccScience Publishing / TD / Volume 2 / Issue 1 / DOI: 10.36922/td.244
Cite this article
60
Download
1117
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW

Receptors of advanced glycation end products in oral squamous cell carcinoma: A systematic review

Sinduja Palati1* Pratibha Ramani1 Saravanan Sekaran1
Show Less
1 Department of Oral and Maxillofacial pathology, Saveetha Dental College and Hospitals, Saveetha Institute for Medical and Technical Sciences, Chennai, Tamil Nadu, India
Tumor Discovery 2023, 2(1), 244 https://doi.org/10.36922/td.244
Submitted: 2 November 2022 | Accepted: 27 January 2023 | Published: 10 February 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

Oxidative stress markers have been shown to be elevated in oral squamous cell carcinomas; plays a crucial role in the build-up of advanced glycation end-receptors of advanced glycation end (AGE-RAGE) products; and has been shown to exacerbate cellular dysfunction, vascular change, apoptosis, and activate inflammatory pathways. The purpose of this study is to assess comprehensively the involvement of RAGE in oral squamous cell malignancies. The findings imply that these receptors and their associated ligands play a significant role in the growth and spread of the tumor, hence impacting the prognosis and life expectancy of the affected individual. This comprehensive review uncovers promising evidence for the clinical use of these molecules, such as RAGEs, in prognostic considerations or as molecular targets for therapy. The available literature shows a role for RAGE in invasion, migration, and angiogenesis in oral cancers. These preliminary findings are encouraging for the therapeutic use of these molecules for prognostic considerations or molecularly targeted therapy.

Keywords
Receptors of advanced glycation end products
Advanced glycation end products
Oral squamous cell carcinoma
Oral cancers
Funding
None.
References
[1]

Scully C, Bagan J, 2009, Oral squamous cell carcinoma overview. Oral Oncol, 45(4–5): 301–308. https://doi.org/10.1016/j.oraloncology.2009.01.004

[2]

López-Graniel CM, de León DT, Meneses-García A, et al., 2001, Tumor angiogenesis as a prognostic factor in oral cavity carcinomas. J Exp Clin Cancer Res, 20(4): 463–468.

[3]

Hofmann MA, Drury S, Fu C, et al., 1999, RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell, 97(7): 889–901. https://doi.org/10.1016/s0092-8674(00)80801-6

[4]

Hori O, Brett J, Slattery T, et al., 1995, The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem, 270(43): 25752–25761. https://doi.org/10.1074/jbc.270.43.25752 

[5]

Sugaya K, Fukagawa T, Matsumoto K, et al., 1994, Three genes in the human MHC class III region near the junction with the class II: Gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics, 23(2): 408–419. https://doi.org/10.1006/geno.1994.1517

[6]

Vissing H, Aagaard L, Tommerup N, et al., 1994, Localization of the human gene for advanced glycosylation end product-specific receptor (AGER) to chromosome 6p21.3. Genomics, 24(3): 606–608. https://doi.org/10.1006/geno.1994.1676

[7]

Bierhaus A, Humpert PM, Morcos M, et al., 2005, Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl), 83(11): 876–886. https://doi.org/10.1007/s00109-005-0688-7

[8]

Taguchi A, Blood DC, del Toro G, et al., 2000, Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 405(6784): 354–360. https://doi.org/10.1038/35012626

[9]

Schmidt AM, Stern DM, 2001, Receptor for age (RAGE) is a gene within the major histocompatibility class III region: Implications for host response mechanisms in homeostasis and chronic disease. Front Biosci J Virtual Libr, 6(3): 1151–1160. https://doi.org/10.2741/schmidt 

[10]

Choi J, Lee MK, Oh KH, et al., 2011, Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori J, 97(2): 196–202. https://doi.org/10.1177/030089161109700211

[11]

Kierdorf K, Fritz G, 2013, RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol, 94(1): 55–68. https://doi.org/10.1189/jlb.1012519

[12]

Bergers G, Benjamin LE, 2003, Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3(6): 401–410. https://doi.org/10.1038/nrc1093

[13]

Carmeliet P, 2005, VEGF as a key mediator of angiogenesis in cancer. Oncology, 69 Suppl 3: 4–10. https://doi.org/10.1159/000088478

[14]

Shweiki D, Itin A, Soffer D, et al., 1992, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359(6398): 843–845. https://doi.org/10.1038/359843a0

[15]

Ko SY, Ko HA, Shieh TM, et al., 2014, Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro. PLoS One, 9(10): e110542. https://doi.org/10.1371/journal.pone.0110542

[16]

Sasahira T, Kirita T, Bhawal UK, et al., 2007, Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology, 51(2): 166–172. https://doi.org/10.1111/j.1365-2559.2007.02739.x

[17]

Hutajulu SH, Paramita DK, Santoso J, et al., 2018, Correlation between vascular endothelial growth factor-A expression and tumor location and invasion in patients with colorectal cancer. J Gastrointest Oncol, 9(6): 1099–1108. https://doi.org/10.21037/jgo.2018.07.01

[18]

Kukreja I, Kapoor P, Deshmukh R, et al., 2013, VEGF and CD 34: A correlation between tumor angiogenesis and microvessel density-an immunohistochemical study. J Oral Maxillofac Pathol, 17(3): 367–373.https://doi.org/10.4103/0973-029X.125200 

[19]

Su S, Chien M, Lin C, et al., 2015, RAGE gene polymorphism and environmental factor in the risk of oral cancer. J Dent Res, 94(3): 403–411. https://doi.org/10.1177/0022034514566215

[20]

Palanissami G, Paul SF, 2018, RAGE and its ligands: Molecular interplay between glycation, inflammation, and hallmarks of cancer-a review. Horm Cancer, 9(5): 295–325. https://doi.org/10.1007/s12672-018-0342-9 

[21]

Bhawal UK, Ozaki Y, Nishimura M, et al., 2005, Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology, 69(3): 246–255. https://doi.org/10.1159/000087910

[22]

Landesberg R, Woo V, Huang L, et al., 2008, The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol, 105(5): 617–624. https://doi.org/10.1016/j.tripleo.2007.08.006

[23]

Sasahira T, Kirita T, Bhawal UK, et al., 2007, The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch, 450(3): 287–295. https://doi.org/10.1007/s00428-006-0359-2

Conflict of interest
The authors declare no conflicts of interest.
Share
Back to top
Tumor Discovery, Electronic ISSN: 2810-9775 Published by AccScience Publishing